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Abstract
Recently, efforts have been focused on mitochondrial DNA changes and their relation to human cancers. Among
them, a 4977 bp deletion of mitochondrial DNA, named “common deletion”, has been investigated in several types of
tumors, with inconsistent results. In this study, we investigated the presence of the common deletion in tissues from
25 breast, 25 colorectal and 50 thyroid tumors and in the adjacent healthy tissues from Turkish patients. Samples
from healthy volunteers were also evaluated for comparison. Two PCR-based methods were used for the detection
of the common deletion. First, two pairs of primers were used to amplify wild-type and deleted mtDNA. Then, a highly
sensitive nested-PCR was performed, to determine low amounts of deleted genomes. By the first method, wild-type
mtDNAs were observed in all samples, but a deletion was observed in only six thyroid samples, by using the
nested-PCR method. In conclusion, the mitochondrial common deletion was very rare in our study group and did not
appear to be not related with cancer.
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Human mitochondrial DNA (mtDNA) is a 16,569-bp
circular double-stranded DNA molecule that encodes 13
subunits of the respiratory chain complexes, two ribosomal
RNAs, and 22 transfer RNAs. Each nucleated human cell
contains a few thousand copies of mtDNA. The somatic
mutation rate of mtDNA is presumed to be 10 to 20 times
higher than that of nuclear DNA, due to close proximity to
the site of reactive oxygen species formation, lack of his-
tones and relatively decreased capacity for repair (Wallace,
1992). There is increasing evidence that mitochondrial
gene mutations including large deletions, missense,
frameshift mutations, and small deletions/insertions are as-
sociated with various types of cancer (Polyak et al., 1998;
Fliss et al., 2000; Penta et al., 2001; Modica-Napolitano
andSingh,2004;AralandÖzer,2007).Amongthesemuta-
tions, a specific deletion of 4977 bp, called the `common
deletion’(mtDNA
4977mutation),wasexaminedinseveral
human tumors as well as in several metabolic and
neurodegenerative disorders, but the results were inconsis-
tent (Maximo et al., 2002; Abnet et al., 2004; Dani et al.,
2004; Zhu et al., 2004; Ye et al., 2008). The deletion re-
moves a 4977 bp section of mitochondrial DNA that en-
compasses five tRNA genes and seven polypeptide genes
which encode sub-units of cytochrome c oxidase, complex
I and ATPase, between nucleotide positions 8470 and
13447, involving two 13 bp repeats (Soong and Arnheim,
1996). In this study, we investigated the association of the
mtDNA common deletion in Turkish patients with breast,
colorectal and thyroid tumors.
Paraffin-embedded tissue specimens from primary
tumors and matched non-neoplastic adjacent tissues were
selected from a total of 100 cancer patients. Briefly, 6 m
thick sections were cut from blocks that had been selected
for maximal tumor content. Total DNA was isolated from
these thin sections as described by Soong and Iacopetta
(1997), following deparaffinization with xylene. Control
DNAfrombloodsamplesof49healthyvolunteerswasalso
extracted, using proteinase K digestion followed by phe-
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The mitochondrial common deletion was determined
bytwodifferenttechniques.Primerlocationsforeachtech-
nique are schematized in Figure 1a and b. The first method
involves two sets of primers: Mitout-F (5’-CCCAACT
AAATACTACCGTATGG-3’) and Mitout-R (5’-GGCTC
AGGCGTTTGTGTATGAT-3’) (outside the deletion re-
gion); and Mitin-F (5’-CTGAGCCTTTTACCACTCCAG-
3’) and Mitin-R (5’-GGTGATTGATACTCCTGATGCG-
-3’) (within the deletion region) (Soong and Arnheim,
1996; Maximo et al., 2002) (Figure 1a). In the wild-type
mtDNA, only the Mitin primer set yields a PCR product
with 142 bp. In cases with the mtDNA common deletion,
Mitin primers amplify a 142-bp target sequence, and
Mitout primers an aberrant PCR product with 214 bp. PCR
amplifications were performed in a total volume of 25 L
containing 200 mol/L of each dNTP, 12.5 pmol of each of
the forward and reverse primers, 50 mmol/L KCl,
10mmol/LTris-HCl,(pH9.0),1.5mmol/LMgCl2,and1U
of Taq DNA polymerase (Fermentas, Lithuania). Cycling
conditions included a single predenaturation step at 94 °C
for 5 min, followed by 35 cycles of denaturation at 94 °C
for 20 s, annealing at 60 °C for 20 s, elongation at 72 °C for
20 s, and a final incubation at 72 °C for 2 min. The PCR
products were visualized on 2% agarose gels stained with
ethidium bromide. Secondly, in order to exclude experi-
mental false results and to detect extremely low levels of
deletion, we applied a nested-PCR method (Soong and
Arnheim, 1996). Primers MT1 (5’-AATTCCCCTAAAA
ATCTTTGAAAT-3’) and MT3 (5’-AGGCGCTATCAC
CACTCTTGTTCG-3’) were used for the primary PCR re-
action (see Fig. 1b for primer positions). These primers are
locatedjustoutsidethe13bprepeatswherethedeletionoc-
curs. One microliter of this primary PCR reaction was then
used as a template for the secondary reactions, using prim-
ers MT2 (5’-GCGATGAGAGTAATAGATAGGGCTCA
GGCG-3’) and MT3. Cycling conditions for both primary
and secondary reactions were similar to those described for
the first method. A 303 bp product was examined by elec-
trophoresis on 2% agarose gels in the samples with the
common deletion.
In this study, we searched for the presence of the mi-
tochondrial 4977 bp common deletion in cancerous and
healthy tissue samples from 25 breast, 25 colorectal and 50
thyroid cancer patients. Type or locations of the tumors,
along with age and gender data of the patients are summa-
rizedinTable1.Themeanageofthebreastcancerpatients,
who were all female, was 59  13.8 years. Regarding
colorectal cancer patients, the mean age was 62.4  10.2
years, and 12 out of the 25 cases were male. The mean age
ofthethyroidcancerpatientswas37.615.8years,with27
male and 23 female patients. In all the breast and colorectal
cancersamples,adjacenthealthytissueswereavailable,but
in seven of the thyroid cancer samples, there was no adja-
cent healthy tissue. Blood samples were obtained from 49
healthy volunteers (10 male and 39 female) with a mean
age of 59.2  12 years.
At first, we successfully amplified mitochondrial ge-
nome from all samples using the Mitin primer pair (Figure
1a), which allows amplification of wild-type mtDNA.
Then, in order to determine the common deletion, samples
including tumors, adjacent healthy tissues and healthy con-
trols were amplified using the Mitout primer pairs, but no
common deletion was detected. As previously mentioned
by Soong and Arnheim (1996), to detect and measure low
levels of deletion in tissues, high sensitivity as well as dis-
crimination between the few molecules of deleted mtDNA
and the overwhelming excess of wt-mtDNA molecules are
required. These authors suggested concentrating the DNA
sample, using radioactively labeled primers or nested-PCR
to detect extremely low levels of deletion. In principle, by
using the nested-PCR protocol, it is possible to concentrate
deleted molecules at the first PCR step and detect single
molecules. Thus, all samples (tumor and adjacent healthy
tissues and control blood) were then re-amplified using the
more sensitive nested-PCR method (see Figure 1b). The
mtDNA common deletion was present in only six samples
from thyroid cancer patients, whereas this deletion was not
observed in the samples from breast or colorectal cancer
patients or from healthy volunteers. The deletion-carrying
cases are summarized in Table 2. As seen in this table, one
casehadthemutationinboththecancerousanditsadjacent
healthy tissues (case ID 69). Two cases had the common
deletioninthecanceroustissues,butnotinthehealthyadja-
cent tissues (cases 33 and 68). One sample presenting the
deletion (case ID 62) in the cancerous tissue had no match-
ing adjacent healthy tissue available to be evaluated.
PreviousstudiesconcerningthemtDNAcommonde-
letion and cancer have shown inconsistent results. An asso-
ciation of the mtDNA common deletion with a variety of
human cancers, including Hürthle cell carcinoma of the
thyroid, esophageal squamous cell carcinoma, thyroid and
hepatocellular cancers has been reported (Maximo et al.,
2002; Abnet et al., 2004). In contrast, several studies
showed no significant association with either lung or
breast, head and neck, colorectal and gastric carcinomas
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Figure 1 - Location of primers in the mitochondrial genome.(Danietal.,2004;Zhuetal.,2004;Yeetal.,2008).Thisin-
consistency may be due to the laboratory techniques ap-
plied and intrinsic features of samples available for each
study (e.g., fresh frozen tissue versus formalin fixed, age
and ethnic background of patients, and so on), as noted by
Ye et al. (2008). The role of the mtDNA common deletion
in carcinogenesis is so far not clear. The mutation may rep-
resent a functional disadvantage for the growth of tumor
cells (Ye et al., 2008). In the present study, we applied two
PCR-based methods to investigate the association of the
mtDNA common deletion with breast, colorectal and thy-
roid tumors in Turkish patients. The mitochondrial DNA
common deletion was very rare in either the cancerous or
non-tumoral tissues of the patient groups and in healthy
controls, suggesting that the deletion is not related with the
examined cancer types. The mitochondrial common dele-
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Table 2 - Summary of the thyroid cancer cases carrying the mtDNA common deletion.
Case ID Type of tumor Patient’s age and gender Tumor Adjacent healthy tissue
33 Follicular adenoma 55, Female Yes No
43 Papillary carcinoma 61, Female No Yes
62 Papillary carcinoma 53, Male Yes Not available
63 Papillary carcinoma 44, Female No Yes
68 Papillary carcinoma 29, Male Yes No
69 Follicular carcinoma 27, Male Yes Yes
Table 1 - Clinical characteristics of the study population.
Type of tumor Mean age  SD No. of patients and gender
Breast cancer Invasive ductal carcinoma 56.4  14.9 13 Females
Infiltrative ductal carcinoma 56.1  10.1 7 Females
Infiltrative apocrine carcinoma 60 1 Female
Inflammatory lobular carcinoma 77 1 Female
Ductal carcinoma in situ 71 1 Female
Atypical medullary carcinoma 77 1 Female
Unknown 77 1 Female
Colorectal cancer Location of the tumor Mean age  SD No. of patients and gender
Ascending colon 68  25.4 2 Females
Descending colon 58  14.8 4 Males
Cecum 59  9.2 2 Males, 1 Female
Sigmoid colon 63  8.4 1 Male, 3 Females
Rectum 58.5  7.8 3 Males, 3 Females
Transverse colon 69.5  7.7 2 Females
Recto-sigmoid region 61 1 Female
Splenic flexure 73.5  0.7 1 Male, 1 Female
Descending + sigmoid colon 65 1 Male
Thyroid cancer Type of tumor Mean age  SD No. of patients and gender
Papillary carcinoma 40.2  17.2 12 Males, 7 Females
Follicular adenoma 35.9  15.5 11 Males, 8 Females
Follicular carcinoma 36  17.3* 3 Males, 2 Females
Medullary carcinoma 38** 1 Male, 1 Female
Anaplastic carcinoma 50 1 Female
Oncocytic adenoma 21 1 Male
Papillary carcinoma + Hashimoto’s thyroiditis 26*** 2 Females
Unknown unknown 1 Female
*: Ages of one male and one female patients with follicular carcinoma were unknown.
**: Age of one male patient with medullary carcinoma was unknown.
***: Age of one female patient with papillary carcinoma + Hashimoto’s thyroiditis was unknown.tion was detected in six thyroid tumor cases only by the
nested-PCR method. This result shows that the method
used to detect the mtDNA common deletion is crucial.
Availability of both tumoral and non-tumoral adjacent tis-
sues from almost all patients and the use of two different
techniques were the strengths of this study. On the other
hand, the relatively small number of patients was its main
limitation, and further studies with larger cohorts are
needed.
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